Mechanisms of delivery of ubiquitylated proteins to the proteasome: new target for anti-cancer therapy? - PubMed (original) (raw)
Review
Mechanisms of delivery of ubiquitylated proteins to the proteasome: new target for anti-cancer therapy?
Rosa Farràs et al. Crit Rev Oncol Hematol. 2005 Apr.
Abstract
The proteasome is the main proteolytic machinery of the cell. It is responsible for the basal turnover of many intracellular polypeptides, the elimination of abnormal proteins and the generation of the vast majority of peptides presented by class I major histocompatibility complex molecules. Proteasomal proteolysis is also involved in the control of virtually all cellular functions and major decisions through the spatially and timely regulated destruction of essential cell regulators. Therefore, the elucidation of its molecular mechanisms is crucial for the full understanding of the physiology of cells and whole organisms. Conversely, it is increasingly clear that proteasomal degradation is either altered in numerous pathological situations, including many cancers and diseases resulting from aberrant cell differentiation, or instrumental for the development of these pathologies. This, consequently, makes it an attractive target for therapeutical intervention. There is ample evidence that most cell proteins must be polyubiquitylated prior to proteasomal degradation. If the structure and the mode of functioning of the proteasome, as well as the enzymology of ubiquitylation, are relatively well understood, how substrates are delivered to and recognized by the proteolytic machine has remained mysterious till recently. The recent literature indicates that the mechanisms involved are multiple, complex and exquisitely regulated and provides new potential targets for anti-cancer pharmacological intervention.
Similar articles
- [Proteasomal degradation: from addressing of substrates to therapeutical perspectives].
Andermarcher E, Bossis G, Farras R, Jariel-Encontre I, Piechaczyk M. Andermarcher E, et al. Med Sci (Paris). 2005 Feb;21(2):141-9. doi: 10.1051/medsci/2005212141. Med Sci (Paris). 2005. PMID: 15691484 Review. French. - Ubiquitin-independent- versus ubiquitin-dependent proteasomal degradation of the c-Fos and Fra-1 transcription factors: is there a unique answer?
Basbous J, Jariel-Encontre I, Gomard T, Bossis G, Piechaczyk M. Basbous J, et al. Biochimie. 2008 Feb;90(2):296-305. doi: 10.1016/j.biochi.2007.07.016. Epub 2007 Jul 31. Biochimie. 2008. PMID: 17825471 Review. - Concise review: role and function of the ubiquitin-proteasome system in mammalian stem and progenitor cells.
Naujokat C, Sarić T. Naujokat C, et al. Stem Cells. 2007 Oct;25(10):2408-18. doi: 10.1634/stemcells.2007-0255. Epub 2007 Jul 19. Stem Cells. 2007. PMID: 17641241 Review. - Alternative UPS drug targets upstream the 26S proteasome.
Hjerpe R, Rodríguez MS. Hjerpe R, et al. Int J Biochem Cell Biol. 2008;40(6-7):1126-40. doi: 10.1016/j.biocel.2007.11.021. Epub 2007 Dec 8. Int J Biochem Cell Biol. 2008. PMID: 18203645 Review. - Fluorescent reporters for the ubiquitin-proteasome system.
Salomons FA, Verhoef LG, Dantuma NP. Salomons FA, et al. Essays Biochem. 2005;41:113-28. doi: 10.1042/EB0410113. Essays Biochem. 2005. PMID: 16250901 Review.
Cited by
- JunB breakdown in mid-/late G2 is required for down-regulation of cyclin A2 levels and proper mitosis.
Farràs R, Baldin V, Gallach S, Acquaviva C, Bossis G, Jariel-Encontre I, Piechaczyk M. Farràs R, et al. Mol Cell Biol. 2008 Jun;28(12):4173-87. doi: 10.1128/MCB.01620-07. Epub 2008 Apr 7. Mol Cell Biol. 2008. PMID: 18391017 Free PMC article. - Magnetic fluid hyperthermia enhances cytotoxicity of bortezomib in sensitive and resistant cancer cell lines.
Alvarez-Berríos MP, Castillo A, Rinaldi C, Torres-Lugo M. Alvarez-Berríos MP, et al. Int J Nanomedicine. 2014;9:145-53. doi: 10.2147/IJN.S51435. Epub 2013 Dec 20. Int J Nanomedicine. 2014. PMID: 24379665 Free PMC article. - Ubiquitin-independent proteasomal degradation of Fra-1 is antagonized by Erk1/2 pathway-mediated phosphorylation of a unique C-terminal destabilizer.
Basbous J, Chalbos D, Hipskind R, Jariel-Encontre I, Piechaczyk M. Basbous J, et al. Mol Cell Biol. 2007 Jun;27(11):3936-50. doi: 10.1128/MCB.01776-06. Epub 2007 Mar 19. Mol Cell Biol. 2007. PMID: 17371847 Free PMC article. - Emerging roles of ATF2 and the dynamic AP1 network in cancer.
Lopez-Bergami P, Lau E, Ronai Z. Lopez-Bergami P, et al. Nat Rev Cancer. 2010 Jan;10(1):65-76. doi: 10.1038/nrc2681. Nat Rev Cancer. 2010. PMID: 20029425 Free PMC article. Review.